Description: Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.
Home Page: www.medicure.com
MPH Technical Analysis
2-1250 Waverley Street
Winnipeg,
MB
R3T 6C6
Canada
Phone:
204 487 7412
Officers
| Name | Title |
|---|---|
| Dr. Albert David Friesen Ph.D. | Founder, CEO & Chairman of the board |
| Dr. Neil Owens Ph.D. | Pres & COO |
| Mr. Haaris Uddin B.Com., CPA | Chief Financial Officer |
| Dr. Reuben Saba Ph.D. | VP of Scientific & Medical Affairs |
| Ms. Jamie Gowryluk | VP of Commercial Operations |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 13.4771 |
|---|---|
| Trailing PE: | 4.1154 |
| Price-to-Book MRQ: | 0.538 |
| Price-to-Sales TTM: | 0.4352 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |